Storia in 2 fonti

Hemab Advances Bleeding Disorder Pipeline - Hemab Therapeutics Hldgs (NASDAQ:COAG)

Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Hemab reports new HMB-002 Von Willebrand disease data, and introduced HMB-003, targeting heavy menstrual bleeding.

Hemab Therapeutics (COAG) presented new clinical data from HMB-002 in Von Willebrand disease, VWD, and announced the HMB-003 program at the Inte...